Insider Selling: Bicara Therapeutics (NASDAQ:BCAX) Insider Sells 5,500 Shares of Stock

Key Points

• Insider sale: Director David Raben sold 5,500 Bicara shares on April 27 at an average price of $22.88 (total $125,840) under a pre‑arranged Rule 10b5‑1 plan, trimming his stake to 55,286 shares (a 9.05% reduction), after also selling 16,500 shares in early March.
• Market and analyst context: BCAX traded around $21.92 (52‑week range $7.80–$24.25) with a $1.44B market cap, and analysts hold a consensus "Moderate Buy" with a $28 target (8 Buys, 3 Holds, 1 Sell) and several higher targets up to $42.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) insider David Raben sold 5,500 shares of the stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $22.88, for a total value of $125,840.00. Following the sale, the insider owned 55,286 shares of the company's stock, valued at $1,264,943.68. This represents a 9.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Raben also recently made the following trade(s):

• On Tuesday, March 3rd, David Raben sold 200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.45, for a total value of $3,690.00.
• On Wednesday, March 4th, David Raben sold 16,300 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.52, for a total value of $301,876.00.

Bicara Therapeutics Price Performance

Shares of NASDAQ:BCAX traded down $0.56 during trading on Tuesday, hitting $21.92. 262,916 shares of the company's stock were exchanged, compared to its average volume of 548,325. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $24.25. The business's 50-day simple moving average is $19.82 and its 200 day simple moving average is $17.84. The company has a market cap of $1.44 billion, a price-to-earnings ratio of -8.66 and a beta of -1.23.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its earnings results on Monday, March 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.04. On average, sell-side analysts anticipate that Bicara Therapeutics Inc. will post -2.72 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently issued reports on BCAX shares. Citigroup began coverage on Bicara Therapeutics in a research report on Thursday, January 29th. They set an "outperform" rating for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Bicara Therapeutics in a report on Wednesday, April 8th. Bank of America began coverage on Bicara Therapeutics in a report on Wednesday, March 25th. They set a "buy" rating and a $35.00 price target for the company. Wedbush restated an "outperform" rating and set a $30.00 price target on shares of Bicara Therapeutics in a report on Tuesday, March 31st. Finally, HC Wainwright raised their price target on Bicara Therapeutics from $40.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday, March 31st. Eight analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Bicara Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $28.00.

Hedge Funds Weigh In On Bicara Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Deutsche Bank AG increased its position in shares of Bicara Therapeutics by 0.9% during the 4th quarter. Deutsche Bank AG now owns 128,626 shares of the company's stock valued at $2,165,000 after purchasing an additional 1,171 shares during the last quarter. Legal & General Group Plc increased its position in shares of Bicara Therapeutics by 64.1% during the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock valued at $29,000 after purchasing an additional 1,233 shares during the last quarter. Mariner LLC increased its position in shares of Bicara Therapeutics by 3.0% during the 4th quarter. Mariner LLC now owns 64,562 shares of the company's stock valued at $1,087,000 after purchasing an additional 1,902 shares during the last quarter. Invesco Ltd. increased its position in shares of Bicara Therapeutics by 13.2% during the 2nd quarter. Invesco Ltd. now owns 16,877 shares of the company's stock valued at $157,000 after purchasing an additional 1,962 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Bicara Therapeutics during the 4th quarter valued at approximately $45,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.